BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10188909)

  • 21. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.
    Christian JA; Cook GJ; Harmer C
    Br J Cancer; 2003 Jul; 89(2):258-61. PubMed ID: 12865913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.
    de Kerviler E; Cadiot G; Lebtahi R; Faraggi M; Le Guludec D; Mignon M
    Eur J Nucl Med; 1994 Nov; 21(11):1191-7. PubMed ID: 7859770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
    Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
    World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
    Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
    J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
    Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
    J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J; Abós MD; Prats E; Delgado M; Razola P; García S; Gomollón F; García F
    Rev Esp Med Nucl; 2001 Feb; 20(1):11-8. PubMed ID: 11181324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
    Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
    Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
    Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer.
    Skånberg J; Ahlman H; Benjegård SA; Fjälling M; Forssell-Aronsson EB; Hashemi SH; Nilsson O; Suurkula M; Jansson S
    Breast Cancer Res Treat; 2002 Jul; 74(2):101-11. PubMed ID: 12186370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
    Baudin E; Schlumberger M; Lumbroso J; Travagli JP; Caillou B; Parmentier C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2541-4. PubMed ID: 8675574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
    Dörr U; Sautter-Bihl ML; Bihl H
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
    [No Abstract]   [Full Text] [Related]  

  • 35. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indium-111-DTPA-octreotide scintigraphy modulation by treatment with unlabelled somatostatin analogue in small-cell lung cancer.
    Soresi E; Bombardieri E; Chiti A; Boffi R; Invernizzi G; Crippa F; Maffioli L
    Tumori; 1995; 81(2):125-7. PubMed ID: 7778214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
    Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
    J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector.
    Rogers BE; McLean SF; Kirkman RL; Della Manna D; Bright SJ; Olsen CC; Myracle AD; Mayo MS; Curiel DT; Buchsbaum DJ
    Clin Cancer Res; 1999 Feb; 5(2):383-93. PubMed ID: 10037188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.
    Krenning EP; Kwekkeboom DJ; de Jong M; Visser TJ; Reubi JC; Bakker WH; Kooij PP; Lamberts SW
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):6-14. PubMed ID: 7992084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.